{
    "nctId": "NCT02613208",
    "briefTitle": "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer",
    "officialTitle": "Observational and Prospective Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER 2-Negative and Aggressive Disease Criteria",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 111,
    "primaryOutcomeMeasure": "Percentage of Participants With Clinical Benefit",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with HER2-negative metastatic breast cancer. Mandatory to have the HER2/estrogen receptor (ER)/progesterone receptor (PR) status\n* Participant who met criteria for first-line treatment with chemotherapy plus bevacizumab (standard doses) by local, regional or national guidelines or authorities\n* Participants with measurable disease (RECIST criteria v1.1) or participants with no measurable but assessable disease\n* Molecular phenotype as triple negative metastatic breast cancer; and ER-positive tumors need to fulfill at least one of the two clinical criteria: metastatic relapse on adjuvant endocrine therapy or progression to at least one prior line of endocrine therapy for advanced disease; or aggressive disease criteria (at least two criteria): taxane based regimen in the (neo) adjuvant setting; metastatic relapse within 2 years from the end of chemotherapy for early breast cancer; liver metastasis; three or more organs with metastatic involvement; symptomatic visceral disease\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n\nExclusion Criteria:\n\n* Participant has received prior chemotherapy for metastatic disease\n* Participant requiring major/minor surgery within 3 weeks prior to administration of the first dose of study treatment\n* Participant has received an investigational therapy within 4 weeks prior to study entry\n* Participant has known symptomatic brain metastases\n* Participant with non-measurable or assessable disease: exclusive blastic bone disease; pleural, pericardial or abdominal effusion as only evidence of disease\n* Participant in chronic daily treatment with corticosteroids (doses greater than \\[\\>\\]10 milligrams per day \\[mg/day\\] of methylprednisolone or equivalent), except inhaled steroids\n* Pregnant or breastfeeding participant\n* Women of childbearing potential who are not using hormonal contraceptives or highly effective birth control during the study\n* Participant has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n* Participant with significant renal, hematological or liver function alteration according to investigator's criteria\n* Participant has serious medical risk factors involving any of the major organ systems",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}